Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and TACE in Unresectable HCC
NCT02908165Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Jun 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sorafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Yale University. Primary endpoints: Tumor Response using Response Evaluation Criteria in Solid Tumors at 54 weeks, Tumor Response using mRECIST at 54 weeks and 1 more. Planned start Jun 2016; status: withdrawn.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02908165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908165.